Claims for Patent: 12,364,685

Summary for Patent: 12,364,685

Title:	Isoxazoline parasiticide formulations
Abstract:	Disclosed herein are compositions which can be used in methods for treating or preventing ophthalmic and dermatologic conditions in a human subject, including ocular surface conditions such as blepharitis or rosacea. The compositions can be topically administered directly to an eye, eyelid, or eyelashes of the patient for targeted local activity.
Inventor(s):	Bobak Robert Azamian, Douglas Michael Ackermann, Shawn D. Hickok, Joseph G. Vehige
Assignee:	Tarsus Pharmaceuticals Inc
Application Number:	US18/897,889
Patent Claims:	1. An isoxazoline parasiticide ophthalmic composition comprising lotilaner, wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition, and wherein the composition is in eye drop form and is formulated for ophthalmic use. 2. The isoxazoline parasiticide ophthalmic composition of claim 1, wherein the lotilaner is present from about 0.15% to about 0.40% by weight with respect to the total weight of the composition. 3. The isoxazoline parasiticide ophthalmic composition of claim 1, wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition. 4. The isoxazoline parasiticide ophthalmic composition of claim 1, wherein the ophthalmic composition does not include any essential oils. 5. The isoxazoline parasiticide ophthalmic composition of claim 1, further comprising castor oil. 6. The isoxazoline parasiticide ophthalmic composition of claim 1, further comprising polyethyoxylated castor oil. 7. The isoxazoline parasiticide ophthalmic composition of claim 6, wherein the polyethyoxylated castor oil is present from about 1% to about 5% by weight with respect to the total weight of the composition. 8. The isoxazoline parasiticide ophthalmic composition of claim 6, wherein the polyethyoxylated castor oil is present at about 5% by weight with respect to the total weight of the composition. 9. The isoxazoline parasiticide ophthalmic composition of claim 1, further comprising a thickening agent. 10. The isoxazoline parasiticide ophthalmic composition of claim 9, wherein the thickening agent comprises hydroxypropylmethylcellulose. 11. The isoxazoline parasiticide ophthalmic composition of claim 1, further comprising a chelating agent. 12. The isoxazoline parasiticide ophthalmic composition of claim 11, wherein the chelating agent comprises edetate disodium. 13. The isoxazoline parasiticide ophthalmic composition of claim 1, further comprising a tonicity agent. 14. The isoxazoline parasiticide ophthalmic composition of claim 13, wherein the tonicity agent is glycerin. 15. The isoxazoline parasiticide ophthalmic composition of claim 1, wherein the composition has a pH between 7 and 7.5. 16. An isoxazoline parasiticide ophthalmic composition comprising: lotilaner, wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition; a hydrogenated castor oil; and a polysaccharide thickener, wherein the composition is formulated for ophthalmic use. 17. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition is in eye drop form. 18. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition is formulated as a gel. 19. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition. 20. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the hydrogenated castor oil is present at about 5% by weight with respect to the total weight of the composition. 21. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the polysaccharide thickener comprises hydroxypropyl methylcellulose or carboxymethyl cellulose. 22. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the polysaccharide thickener is present at between about 0.1% and about 0.5% by weight with respect to the total weight of the composition. 23. The isoxazoline parasiticide ophthalmic composition of claim 22, wherein the polysaccharide thickener is present at about 0.2% by weight with respect to the total weight of the composition. 24. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition further comprises a preservative agent, wherein the preservative agent does not comprise lauralkonium chloride or benzalkonium chloride. 25. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition further comprises a preservative agent, wherein the preservative agent is present at between about 0.15% and about 0.4% by weight with respect to the total weight of the composition. 26. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition does not comprise tea tree oil. 27. The isoxazoline parasiticide ophthalmic composition of claim 16, wherein the ophthalmic composition is only locally therapeutically effective. 28. An isoxazoline parasiticide ophthalmic composition comprising lotilaner, wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition, wherein the ophthalmic composition is in eye drop form and is formulated for ophthalmic use, and wherein the ophthalmic composition is only locally therapeutically effective. 29. An isoxazoline parasiticide ophthalmic composition comprising lotilaner, wherein the ophthalmic composition is formulated as a gel, an ointment, or a cream, and wherein the ophthalmic composition is only locally therapeutically effective. 30. The isoxazoline parasiticide ophthalmic composition of claim 28, wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition, wherein the composition further comprises glycerin, and wherein the composition further comprises about 5% by weight of hydrogenated castor oil. 31. The isoxazoline parasiticide ophthalmic composition of claim 29, wherein the lotilaner is present at about 0.25% by weight with respect to the total weight of the composition, wherein the composition further comprises glycerin, and wherein the composition further comprises about 5% by weight of hydrogenated castor oil. 32. The isooxazoline parasiticide ophthalmic composition of claim 29, wherein the composition is a gel, wherein the lotilaner is present at about 0.50% by weight with respect to the total weight of the composition, and wherein the composition further comprises edetate disodium, castor oil, glycerin, and carboxymethyl cellulose.